Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599228 · ClinicalTrials.gov registry record · NA
Using Virtual Reality to Teach Mindfulness to People With Migraine
A NA study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT07599228: Clinical Trial NA study, sponsored by Brigham and Women's Hospital.
NCT07599228 is a NA study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07599228, a NA study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
The aim of this clinical trial is to learn if people with migraine can learn a type of biobehavioral therapy called Acceptance and Commitment Therapy (ACT) by using a virtual reality headset. Researchers are studying if this type of mindfulness therapy helps to decrease migraine-related disability. Participants will be randomized to treatment as usual or active virtual reality groups for four weeks. Everyone will keep symptom diaries, complete surveys, attend two clinic visits, and have two blood draws.
Primary Outcome
Assessment of user experience captured using open ended questions, yes/no questions, and a 4-point scale ranging from "Very Poor" to "Very Good".
Interventions
- BEHAVIORAL ACT therapy delivered by REACT NeuroVR headset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-01 |
| Phase | NA |
What is known before NCT07599228 opens enrollment
NCT07599228 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which ACT therapy delivered by REACT NeuroVR headset is the first listed.
NCT07599228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07599228 about?
NCT07599228 is a clinical study titled "Using Virtual Reality to Teach Mindfulness to People With Migraine". The aim of this clinical trial is to learn if people with migraine can learn a type of biobehavioral therapy called Acceptance and Commitment Therapy (ACT) by using a virtual reality headset. Researchers are studying if this type of mindfulness therapy helps to decrease migraine-related disability. ...
What is the current status of trial NCT07599228?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2026-07. Estimated completion is 2031-01.
What interventions are being tested in trial NCT07599228?
The interventions under investigation include: ACT therapy delivered by REACT NeuroVR headset (BEHAVIORAL).
Who is sponsoring clinical trial NCT07599228?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07599228's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia